The MDS Beacon™

Trisenox, in combination with low-dose cytarabine, may not provide significant benefit to patients with higher-risk myelodysplastic syndromes, according to a recently-published study.

Trisenox (arsenic trioxide), which has been approved for the treatment for acute promyelocytic leukemia, is also being studied for the treatment of myelodysplastic syndromes (see related Beacon news).

The current study tested the possible benefits of Trisenox in combination with low-dose cytarabine (Cytosar-U), which has been used to treat myelodysplastic syndromes (MDS) for over 25 years.  The study evaluated the combination therapy in 49 patients with intermediate-…

Trisenox (arsenic trioxide) may have some efficacy in the treatment of myelodysplastic syndromes (MDS), according to a Phase 2 study conducted by Italian researchers.

The findings were presented at the 51^st annual American Society of Hematology (ASH) Meeting and Exposition in New Orleans on December 8.

Trisenox is an FDA-approved therapeutic agent for the treatment of certain types of leukemia. It is currently being studied for use in the treatment of high- and low-risk MDS. In vitro studies, which are those performed in controlled environments like test tubes or Petri…